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Bats are implicated as the natural reservoirs for several highly pathogenic viruses that can infect other 
animal species, including man. Here, we investigate the potential for two recently discovered bat 
rubulaviruses, Achimota virus 1 (AchPV1) and Achimota virus 2 (AchPV2), isolated from urine collected 
under urban bat (Eidolon helvum) roosts in Ghana, West Africa, to infect small laboratory animals. 
AchPV1 and AchPV2 are classified in the family Paramyxoviridae and cluster with other bat derived 
zoonotic rubulaviruses (i.e. Sosuga, Menangle and Tioman viruses). To assess the susceptibility of 
AchPV1 and AchPV2 in animals, infection studies were conducted in ferrets, guinea pigs and mice. 
Seroconversion, immunohistological evidence of infection, and viral shedding were identified in 
ferrets and guinea pigs, but not in mice. Infection was associated with respiratory disease in ferrets. 
Viral genome was detected in a range of tissues from ferrets and guinea pigs, however virus isolation 
was only achieved from ferret tissues. The results from this study indicate Achimota viruses (AchPVs) 
are able to cross the species barrier. Consequently, vigilance for infection with and disease caused by 
these viruses in people and domesticated animals is warranted in sub-Saharan Africa and the Arabian 
Peninsula where the reservoir hosts are present.
New and emerging viral infections impose a significant burden on human health and on the world economy. The 
majority of emerging infectious diseases affecting humans today are of animal origin with approximately three 
quarters arising from wildlife1. Bats have been shown to harbour more zoonotic viruses than other mammalian 
species2,3 and are implicated in outbreaks of a number of highly pathogenic zoonotic viruses, including filovi-
ruses, coronaviruses, paramyxoviruses and reoviruses. Ebola virus (EboV) RNA and antibodies have been discov-
ered in African fruit bats4. The largest human outbreak of EboV occurred in West Africa in 2013–2014, resulting 
in nearly 30,000 infections and 11,000 deaths and took over a year to contain5. SARS coronavirus emerged in 
China in 2002 and infected over 8000 people causing 774 deaths6 and the MERS coronavirus continues to infect 
people and cause death in the Middle East7. Bats have since been found to harbour a multitude of coronaviruses 
closely related to SARS and MERS8,9. Pteropid bats are the reservoir hosts for the deadly henipaviruses, Nipah 
virus (NiV) and Hendra virus (HeV)10,11. NiV continues to cause fatal encephalitis in humans almost annually in 
Bangladesh, while HeV has spilled-over into horses in Australia nearly every year since 2004 and has killed four 
people12,13. Orthoreoviruses have been isolated from bats and humans in Southeast Asia where they have caused 
flu-like illness in people14. Known zoonotic viruses of bat origin continue to be of concern for human and animal 
health, and active surveillance provides our best option for monitoring these agents as well as identifying novel 
pathogens of zoonotic potential.
The recently discovered rubulaviruses, Achimota virus 1 and Achimota virus 2 (AchPV1 and AchPV2), were 
isolated from bat (Eidolon helvum) urine samples collected beneath urban bat roosts in Ghana, West Africa15. 
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AchPV1 and AchPV2 are newly recognised viral species in the family Paramyxoviridae, where they cluster with 
other bat rubulaviruses. Despite being discovered in the same study, the AchPVs are not nearest-phylogenetic rel-
atives and share only 31 to 64% protein amino acid identities15. Their relationship to each other is similar to their 
relationships with other bat rubulaviruses such as Sosuga (SosPV), Menangle (MenPV) and Tioman (TioPV) 
viruses (sharing 58–70% N protein amino acid sequence identities), which have been shown to cause human 
infection. SosPV was isolated from a wildlife biologist studying bats and rodents in Africa in 2012 and is believed 
to be the causative agent for a severe flu-like illness and skin rash16. Follow up investigations revealed the presence 
of this virus in the spleen of Rousettus aegyptiacus bats17. MenPV first emerged in a piggery in NSW, Australia, 
in 1997 causing reproductive disease in pigs18. Two piggery workers had flu-like illness during the outbreak and 
were later found to have MenPV neutralising antibodies. Serological evidence of MenPV infection was also found 
in flying foxes roosting near the piggery and the virus was later isolated from Pteropus alecto urine18,19. TioPV 
was isolated from pteropid bat urine on Tioman Island in 2001 during the search for the reservoir host of Nipah 
virus20. It was later found that humans on the island had neutralising antibodies to TioPV, although no associated 
disease has been reported21.
Based on what is known of these closely related bat rubulaviruses, the potential of AchPV1 and AchPV2 to 
infect and cause disease in other species is worthy of further investigation. Serological surveys of Eidolon helvum 
populations in Africa have been conducted for AchPVs and have shown a widespread presence of neutralising 
antibodies15. In addition, a survey of human sera collected from Ghana and Tanzania detected AchPV2 neutral-
ising antibodies in three of 442 samples tested, however no neutralising antibodies to AchPV1 were detected in 
these sera. Two of the antibody positive samples were from healthy adults and one was from a febrile paediatric 
patient15. These data suggest that AchPV2 is zoonotic, but whether AchPV1 is zoonotic remains unknown.
To further investigate the infection potential of AchPV1 and AchPV2, we conducted studies in three species 
of small laboratory animal; ferret (Mustela putorius furo), guinea pig (Cavia porcellus) and mouse (Mus musculus 
domesticus). First, we conducted observational studies to determine the susceptibility of these animals to infec-
tion by AchPV1 or AchPV2. Second, time course studies were performed using AchPV2 to obtain data on viral 
replication sites and potential routes of transmission.
Results
Observational study with AchPV1 and AchPV2 in ferrets. Two adult male ferrets aged 11–13 months 
were given 105 TCID50 AchPV1 oronasally in 1 ml of inoculum and another two adult male ferrets aged 11–13 
months were given 105 TCID50 AchPV2 oronasally in 1 ml of inoculum. The animals were observed daily for 
clinical signs and then electively euthanased at 21 days post challenge (pc).
One of the two ferrets exposed to AchPV1 remained clinically well and was electively euthanased at the end of 
experiment on day 21 pc. The other ferret showed signs of upper respiratory tract infection (sneezing, coughing) 
and weight loss from day 1 pc, and was euthanased at day 14 pc when it had reached a predetermined humane 
endpoint of 10% bodyweight loss. Post mortem examination revealed a pleural effusion and bronchopneumonia 
of the right intermediate lung lobe. Each ferret developed neutralising antibody against AchPV1, with titres of 
1:320 (healthy) and 1:80 (ill) (Table 1).
One of two ferrets exposed to AchPV2 remained clinically well and was electively euthanased at the end of the 
experiment on day 21 pc. The other ferret maintained normal play activity but showed signs of upper respiratory 
tract infection (sneezing, purulent nasal discharge) from day 3 pc and which resolved by day 11 pc. The animal 
was electively euthanased at the end of the experiment on day 21 pc. Each ferret developed neutralising antibody 
against AchPV2, with titres >1:1280 (healthy) and 1:1280 (ill/recovered) (Table 1).
In summary, it is unclear whether the signs of respiratory tract disease in one of two ferrets given either 
AchPV1 or AchPV2 were attributable to infection by the challenge virus or by co-infection of an unknown patho-
gen. As higher neutralising antibody titres were observed in ferrets infected with AchPV2, and as there was prior 
serological evidence of this virus in people, AchPV2 was selected for a time-course study with ferrets.
Observational study with AchPV1 and AchPV2 in guinea pigs. Four adult female guinea pigs were 
given 105 TCID50 AchPV1 oronasally in 1 ml of inoculum and another four adult female guinea pigs were given 
105 TCID50 AchPV2 oronasally in 1 ml of inoculum. The animals were observed daily for clinical signs and then 
electively euthanased at 21 days pc.
AchPV1 AchPV2
Animal SNT Titre Animal SNT Titre
Ferret 1 1:320 Ferret 1 >1:1280
Ferret 2* 1:80 Ferret 2 1:1280
Guinea Pig 1 1:40 Guinea Pig 1 1:160
Guinea Pig 2 1:80 Guinea Pig 2 1:40
Guinea Pig 3 1:320 Guinea Pig 3 1:80
Guinea Pig 4 1:80 Guinea Pig 4 1:320
Table 1. The serum neutralisation titres against AchPV1 and AchPV2 for ferret and guinea pig serum collected 
21 days pc. The serum collected from the animals pre-challenge (day 0) were all negative. Mouse sera were also 
tested but the data is not shown as they didn’t seroconvert. *This animal became ill and was euthanized at day 
14 pc instead of day 21 pc.
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All four guinea pigs exposed to AchPV1 remained clinically well and were electively euthanased on day 
21 pc. Each guinea pig developed neutralising antibody against AchPV1, with titres of 1:320, 1:80, 1:80 and 
1:40 (Table 1). Similarly, all four guinea pigs exposed to AchPV2 remained clinically well and were electively 
euthanased on day 21 pc. Each guinea pig developed neutralising antibody against AchPV2, with titres of 1:320, 
1:160, 1:80 and 1:40 (Table 1).
Based on the same rationale as for ferrets, AchPV2 was selected for a time-course study with guinea pigs.
Observational study with AchPV1 and AchPV2 in mice. Ten mice (five female BALB/c mice aged 12 
weeks and five female BALB/c mice aged over 12 months) were given 103 TCID50 AchPV1 intranasally in 50 µl of 
inoculum and another ten mice (five female BALB/c mice aged 12 weeks and five female BALB/c mice aged over 
12 months) were given 103 TCID50 AchPV2 intranasally in 50 µl of inoculum. The animals were observed daily for 
clinical signs and then electively euthanased at 21 days pc.
All ten mice exposed to AchPV1 remained clinically well and were electively euthanased on day 21 pc. 
Neutralising antibody against AchPV1 was not detected in any mouse. Likewise, all ten mice exposed to AchPV2 
remained clinically well and were electively euthanased on day 21 pc. Neutralising antibody against AchPV2 was 
not detected in any mouse. As mice had no detectable signs of disease and did not seroconvert to either AchPV1 
or AchPV2, no further studies were conducted with mice.
Time course study with AchPV2 in ferrets. Clinical and Pathological findings. For this study, eight 
adult female ferrets were given 105 TCID50 AchPV2 oronasally in 1 ml of inoculum and then two animals were 
pre-allocated for euthanasia on each of days 6, 8, 10 and 21 pc. All eight ferrets in this study showed a mild but 
significant increase in rectal temperature over baseline on day 4 pc (p = 0.02), and a mild but significant loss of 
bodyweight compared to baseline on days 4 (p = 0.03) and 5 (p = 0.0004) pc (Supplementary Tables S1 and S2). 
Otherwise, the animals remained clinically well until elective euthanasia, apart from one of two ferrets scheduled 
for euthanasia on day 8 pc. This ferret (#9) showed signs of upper respiratory tract infection (sneezing, serous 
and then purulent nasal discharge) between days 2 and 6 pc and was euthanased on humane grounds on day 6 pc 
following markedly decreased play activity. Other than ferret #9, no significant gross abnormalities were observed 
at post mortem examination in any of the ferrets.
The three ferrets euthanased on day 6 pc had minor histopathological changes associated with viral replica-
tion. Ferret #12 (day 6 pc) showed very mild acute bronchiolitis. Immunohistochemistry revealed viral antigen in 
germinal centres of the retropharyngeal lymph node but not in other tissues. In ferret #14 (day 6 pc), significant 
histopathological changes were confined to mild acute tonsillitis, and viral antigen was detected in the tonsillar 
and pharyngeal epithelium, retropharyngeal lymph node (particularly the parafollicular areas), bronchial epithe-
lial cells, bronchus-associated lymphoid tissues (BALT), perivascular spindle cells in lung, and germinal centres 
and periarteriolar lymphoid sheaths of the spleen. In ferret #9, euthanased on day 6 pc with respiratory disease, 
there was moderately severe acute bronchiolitis, hyperplasia of the BALT, excess mucus production by bronchial 
glands, and focal lipoid pneumonia consistent with chronic bronchial disease. Post mortem examination of ferret 
#9 also revealed marked nodular hyperplasia of the liver with hepatic steatosis, but this lesion was considered to 
be unrelated to virus exposure as no AchPV2 viral antigen was detected in the liver.
In ferret #9, AchPV2 viral antigen was identified in tonsillar and pharyngeal epithelium, germinal centres, 
parafollicular area and medulla of the retropharyngeal lymph node, tracheal epithelium, bronchial and bronchi-
olar epithelium (Fig. 1), BALT and perivascular connective tissues of the lung, bronchial and mediastinal lymph 
node, periarteriolar lymphoid sheaths and red pulp of the spleen, mononuclear cells in the intestinal lamina 
propria and cells either within or lining the hepatic sinusoids.
In the single ferret euthanased on day 8 pc (ferret #16), there was mild focal acute tracheitis and bronchiolitis. 
The distribution of viral antigen was similar to ferret #9, with the addition of occasional bile duct epithelial cells 
and mononuclear cells of the portal triads, gut associated lymphoid tissue (GALT), and transitional epithelial 
cells in the bladder.
The two ferrets euthanased on day 10 pc showed only small amounts of viral antigen by immunohistochem-
istry. Ferret #11 (day 10 pc) had mild focal acute bronchiolitis, and detection of viral antigen was limited to small 
amounts in tonsillar lymphoid tissue, bronchiolar epithelial cells, periarteriolar lymphoid sheaths of the spleen, 
and a diffuse scattering throughout the retropharyngeal lymph node. Ferret #13 (day 10 pc) also showed very 
mild acute bronchiolitis, with AchPV2 viral antigen confined to scattered gastric epithelial cells, GALT, and sparse 
deposits throughout tonsillar lymphoid tissue, bronchial and retropharyngeal lymph nodes.
Of the two ferrets euthanased on day 21 pc, one (ferret #15) had very mild acute bronchiolitis and tracheitis 
and one had no detectable lesions. AchPV2 viral antigen was not detected in any tissue from either of these two 
ferrets.
Detection of viral genomes. AchPV2 RNA was detected by RT-qPCR in the oral swabs of 4 ferrets on day 2 pc 
and in all ferrets by day 4 pc until euthanasia: the highest levels were typically recorded on day 6 or 8 pc (Table 2). 
Similar results were seen for the nasal washes: viral RNA was detected in 3 ferrets on day 2 pc, and in all ferrets by 
day 4 pc until euthanasia, the highest levels typically were recorded on day 6 or 8 pc. Rectal swabs first detected 
AchPV2 on day 4 pc, when all ferrets were positive, the highest levels occurred on day 6 or 8 pc. Viral RNA was 
commonly detected in blood samples from days 2 to 21 pc. Where viral RNA was found in successive blood sam-
ples from individual animals, highest levels were recorded on day 6 or 8 pc (Table 2).
All tissue samples analysed from ferrets #9, #12 and #14 euthanased on day 6 pc were positive for viral RNA 
(data summarised in Fig. 2), with the highest levels in bronchial and retropharyngeal lymph nodes and the lowest 
levels in heart, kidney and brain. Each tissue sample tested from ferret #16 (euthanased 8 days pc) was also pos-
itive for viral RNA, with the highest reading in retropharyngeal lymph node. On day 10 pc, ferrets #11 and #13 
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exhibited generally similar distribution and quantities of viral RNA to the animals above. However, on day 21 pc 
the levels of viral RNA in ferrets #10 and #15 were substantially lower, and largely limited to the retropharyngeal 
and bronchial lymph nodes and the spleen.
Virus isolation. Virus was reisolated from the nasal wash and from the oral and rectal swabs of ferret #9 on day 
6 pc, the nasal wash of ferret #10 on day 6 pc, the oral swab of ferret #11 on day 6 pc, and from the oral swabs of 
ferret #16 on days 6 and 8 pc, plus the nasal wash of this ferret on day 8 pc (Table 2).
Virus was reisolated from ferrets killed on day 6 pc from tonsil, bronchial and retropharyngeal lymph nodes, 
lung and brain (ferret #9); trachea, tonsil, bronchial and retropharyngeal lymph nodes, and bladder (ferret #12); 
and tonsil and bronchial and retropharyngeal lymph nodes (ferret #14) (Fig. 2). Virus was reisolated from tonsil 
and trachea of ferret #16 (which was killed on day 8 pc) and from the retropharyngeal lymph node and kidney of 
ferret #13 (day 10 pc), but not from ferret #11 (day 10 pc). Virus re-isolation from ferrets killed on day 21 pc was 
limited to the retropharyngeal lymph node of ferret #15.
Serology. No neutralising antibodies were observed at day 2 or 4 pc but by day 6 low levels of neutralising anti-
bodies were detected in the ferrets (Table 4). They showed an increase in neutralising antibody titre across the 
time points, with the animals bled at day 21 pc having neutralising antibody titres >1:1280.
Time course study with AchPV2 in guinea pigs. Clinical and Pathological findings. For this study, 
eight adult female guinea pigs were given 105 TCID50 AchPV2 oronasally in 1 ml of inoculum and then two 
animals were pre-allocated for euthanasia on each of days 6, 8, 10 and 21 pc. In guinea pigs, there were no sig-
nificant differences in temperature or bodyweight over baseline up to day 6 pc, and the animals remained clini-
cally healthy until elective euthanasia (Supplementary Tables S3 and S4). No significant gross abnormalities were 
observed at post mortem examination, apart from enlarged bronchial lymph nodes in one guinea pig euthanased 
on day 6 pc. The only histopathological changes observed were: mild acute tracheitis in all animals, two animals 
with mild acute bronchitis and/or bronchiolitis, and four with mild chronic interstitial pneumonia attributable to 
inhalation of plant material. In contrast to the observations in ferrets, the pattern of respiratory tract lesions did 
not correlate with the time post-exposure to AchPV2; very few histopathological changes were observed and all 
sections of tissues from all guinea pigs were negative for AchPV2 antigen by immunohistochemistry.
Detection of viral genomes. Low levels of AchPV2 were detected in the oral swab of one guinea pig on day 6 pc 
and of another on day 8 pc (Table 3). Rectal swabs were positive in four of six guinea pigs on day 8 pc, and from 
Figure 1. Viral antigen in bronchiolar epithelial cells and BALT in ferret #9 (polyclonal rabbit anti-AchPV2): 
note also intraluminal acute inflammatory infiltrate, of uncertain pathogenic significance.
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Sample
Days Post Challenge
0 2 4 6 8 10 21
Ferret 9
Oral Swab — — 32.9 24.4***
Rectal swab — — 34.1 24.9**
Nasal wash — 36.8 33 26***
Blood — — NA 31.5
Ferret 12
Oral Swab — — 32.10 21.8
Rectal swab — — 29.50 22.6
Nasal wash — — 31.40 25.1
Blood — 35.9 26.50 NA
Ferret 14
Oral Swab — 36.9 31.90 33
Rectal swab — — 32.20 24.8
Nasal wash — — 31.40 27.1
Blood — 37.8 29.10 28.7
Ferret 16
Oral Swab — 34.5 32.50 22.2* 24*
Rectal swab — — 32.00 22.6 23
Nasal wash — — 34.10 28.3 27**
Blood — — 31.30 30.1 20.9
Ferret 13
Oral Swab — 36 31.50 23.5 24 23.60
Rectal swab — — 29.50 22.8 23.4 23.70
Nasal wash — — 33.60 25.9 22.3 24.50
Blood — — 29.40 29.2 30.8 34.00
Ferret 11
Oral Swab — — 31.9 22.9*** 22 25.30
Rectal swab — — 30.9 22 19.6 25.50
Nasal wash — — 32.00 24.8 22.8 25.00
Blood — — 28.90 NA 27.3 36.10
Ferret 15
Oral Swab — 35 32.90 25.8 20.9 26.50 30
Rectal swab — — 31.30 23.2 22.5 23.70 29
Nasal wash — 34.3 34.20 26.3 25 25.30 30.5
Blood — — 24.70 NA 24 36.00 30
Ferret 10
Oral Swab — — 30.5 30.3 23.3 27.00 31.2
Rectal swab — — 29 23.6 22.4 27.00 32.5
Nasal wash — 37 31.9 25.3** 24.6 26.30 28.5
Blood — — — NA NA 33.80 —
Table 2. Analysis of viral shedding and viraemia in ferrets by RNA detection and virus isolation. Average 
cycle threshold (Ct) values were obtained from testing oral and rectal swabs, nasal washes and blood from 
AchPV2 ferrets using RT-qPCR. KEY:—indicates sample was negative (Av Ct > 38); NA indicates sample was 
unavailable for testing; *indicates virus re-isolated at neat dilution; **indicates virus re-isolated at 1:5 dilution 
and ***indicates virus re-isolated at 1:50 dilution.
Figure 2. Analysis of virus infection in ferrets by RNA detection and virus isolation. Average cycle threshold 
(Ct) values were obtained from testing tissues from AchPV2 ferrets using RT-qPCR. Stars indicate samples that 
AchPV2 was re-isolated from.
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one guinea pig on day 10 pc. Viral RNA was found in the blood of one guinea pig on day 6 pc and of another on 
day 8 pc (both of which had viral RNA-positive oral swabs at these times).
Most tissue samples analysed from guinea pigs euthanased on day 6 and 8 pc were positive for viral RNA 
(data summarised in Fig. 3), with highest levels present in nasal turbinates, bronchial and retropharyngeal lymph 
nodes, and spleen, and lower levels in trachea, lung, and liver. Detection of viral RNA was lowest and inconsistent 
from heart, kidney and brain. By day 10 pc, viral genome detection was limited to bronchial and/or retropharyn-
geal lymph nodes, lung, spleen, and nasal turbinates (one of two animals). On day 21 pc, one guinea pig was nega-
tive by RT-qPCR for all tissues; in the other, viral genome was detected only in bronchial lymph node and spleen.
Virus isolation. Virus was not reisolated from any of the clinical samples, including those that were positive by 
AchPV2-specific RT-qPCR (Table 3). In addition, virus was not reisolated from any tissue sample, including those 
that were positive by AchPV2-specific RT-qPCR (Fig. 3).
Animal SNT Titre Animal SNT Titre
Ferret 9* (Day6) 1:20 G.Pig 1 (Day6) 1:20
Ferret 12 (Day6) 1:40 G.pig 2 (Day6) 1:20
Ferret 14 (Day6) 1:640 G.Pig 3 (Day8) 1:20
Ferret 16 (Day8) 1:640 G.pig 4 (Day8) 1:20
Ferret 11 (Day10) 1:640 G.Pig 5 (Day10) 1:40
Ferret 13 (Day10) >1:1280 G.pig 6 (Day10) 1:40
Ferret 10 (Day21) >1:1280 G.Pig 7 (Day21) 1:160
Ferret 15 (Day21) >1:1280 G.pig 8 (Day21) 1:160
Table 4. The serum neutralisation titres against AchPV2 for ferret and guinea pig serum collected on days 6, 8, 
10 and 21 pc. Sera collected on day 2 and 4 pc were also tested but were negative for neutralising antibodies (data 
not shown). *This animal became ill and was euthanized at day 6 pc instead of day 8 pc.
Sample
Days Post Challenge
0 2 4 6 8 10 21
Guinea Pig 1
Oral Swab — — — —
Rectal swab — — — —
Blood — — — —
Guinea Pig 2
Oral Swab — — — 37.74
Rectal swab — — — —
Blood — — — 35.25
Guinea Pig 3
Oral Swab — — — — 36.44
Rectal swab — — — — 35.09
Blood — — — — 34.71
Guinea Pig 4
Oral Swab — — — — —
Rectal swab — — — — 37.31
Blood — — — — —
Guinea Pig 5
Oral Swab — — — — — —
Rectal swab — — — — — —
Blood — — — — — —
Guinea Pig 6
Oral Swab — — — — — —
Rectal swab — — — — — —
Blood — — — — —
Guinea Pig 7
Oral Swab — — — — — — —
Rectal swab — — — — 35.39 34.97 —
Blood — — — — — — —
Guinea Pig 8
Oral Swab — — — — — — —
Rectal swab — — — — 33.98 — —
Blood — — — — — — —
Table 3. Analysis of viral shedding and viraemia in guinea pigs by RNA detection and virus isolation. Average 
cycle threshold (Ct) values were obtained from testing oral and rectal swabs and blood from AchPV2 guinea 
pigs using RT-qPCR. AchPV2 was unable to be re-isolated from any sample. KEY:—indicates sample was 
negative (Av Ct > 38).
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Serology. No neutralising antibodies were observed at day 2 or 4 pc but by day 6 low levels of neutralising anti-
bodies were detected in the guinea pigs (Table 4). There was a slight increase in neutralising antibody titre across 
the time points with a titre of 1:160 by day 21 pc.
Discussion
We investigated the potential of the two recently discovered bat rubulaviruses, AchPV1 and AchPV2, to infect 
laboratory animals representing three species (ferret, guinea pig and mouse). Seroconversion to both Achimota 
viruses in ferrets and guinea pigs indicated these animals were susceptible to infection, however mice did not 
seroconvert to either virus. Due to their body size, mice were given a lower dose of inoculum, and were chal-
lenged intranasally, rather than via the oronasal route used for the ferrets and guinea pigs. The difference in 
volume and inoculation route may account for the lack of seroconversion seen in the mice, however it is probably 
more likely that this species is resistant to infection. Higher levels of neutralising antibodies were observed in the 
ferrets and guinea pigs infected with AchPV2 compared to those infected with AchPV1. This result reflected in 
vitro data where it was observed previously that AchPV2 consistently grows to a higher titre than AchPV1 in vero 
and PaKi cell lines15. Additionally, respiratory tract disease in one of two ferrets given either AchPV1 or AchPV2 
was seen in the observational studies, although it remains unclear if this was related to Achimota virus infection 
or was entirely due to co-infection by an unknown pathogen. AchPV2 was chosen for a time-course study based 
on two criteria: higher neutralising antibodies observed in ferrets and guinea pigs compared to AchPV1, and pre-
vious evidence of human infection (AchPV2 neutralising antibodies). Given more time and resources, it would 
be worthwhile to do an additional time course study with AchPV1, to further investigate the differences between 
these two viruses.
The AchPV2 time-course studies provided additional evidence that this virus can infect ferrets and guinea 
pigs and revealed viral replication sites and potential routes of transmission. Evidence of infection was supported 
by virus re-isolation from clinical specimens and post-mortem tissue samples, and viral antigen detection in 
tissues by quantitative real-time PCR and immunohistochemistry. Although there was evidence of mild malaise 
in infected ferrets (raised body temperature and weight loss), a distinct clinical syndrome with specific clinical 
signs was not identified in either ferrets or guinea pigs. Moreover, no histological lesions were attributed with 
confidence to infection by AchPV2. Mild tonsillitis, tracheitis and bronchiolitis were recorded in ferrets, but in 
some animals the lesions were identified without evidence of specific association with AchPV2 antigen. The fer-
rets were sourced from a colony free of influenza and canine distemper virus, were clinically healthy at the time 
of exposure to AchPV2, and were not maintained on a particulate substrate. The pathogenesis of these legions 
remains uncertain, although an opportunistic bacterial or other viral aetiology could not be excluded. In other 
tissues, such as bile duct epithelium and transitional epithelial cells of the bladder, viral antigen was seen without 
substantial inflammatory reaction or tissue injury.
For ferrets, following an incubation period of 5 to 6 days, AchPV2 was shed in oral and nasal secretions and 
the development of virus neutralising antibody was generally associated with virus clearance. The results of quan-
titative real-time PCR, virus re-isolation and immunohistochemistry taken together identified the major sites of 
AchPV2 replication in ferrets to be respiratory tract epithelium and associated lymphoid tissues. Virus was able 
to be re-isolated from all of the ferrets at all time points from at least one tissue or clinical sample (swab or nasal 
wash) but not from blood. Although virus was not re-isolated from blood, the development of viremia may be 
inferred by confirmation of infection within spleen and urinary tract epithelium by immunohistochemistry and 
viral genome detection in the blood by quantitative real-time PCR. In the absence of other clinico-pathological 
support for CNS infection, virus in blood may also account for the re-isolation of AchPV2 from one sample of 
ferret brain tissue.
Although exposure to AchPV2 resulted in production of neutralising antibodies in guinea pigs, antibody 
titres were much lower than for the ferrets. Significantly, patterns of viral RNA detection from guinea pigs were 
generally similar to those in ferrets, but virus was not re-isolated from any tissue or clinical sample from guinea 
pigs and viral antigen was not demonstrated in their tissues by immunohistochemistry. The sites of AchPV2 rep-
lication in guinea pigs, therefore, could not be determined with confidence. Our observations suggest that guinea 
pigs are less permissive to AchPV2 infection than ferrets.
Figure 3. Analysis of virus infection in guinea pigs by RNA detection and virus isolation. Average cycle 
threshold (Ct) values were obtained from testing tissues from AchPV2 guinea pigs using RT-qPCR. AchPV2 
was unable to be re-isolated from any sample.
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When assessing the spill-over potential and working up an animal model for a novel virus, it is important to 
use animals from more than one species. There is no reliable method to determine the best species simply by char-
acterising the virus, which is a big limitation of using virus discovery as a stand-alone surveillance strategy for 
zoonotic pathogen discovery. Therefore, it is only possible to do what is practical and feasible in terms of assessing 
potential spill-over hosts. Small laboratory animals such as ferrets, guinea pigs and mice, representing different 
mammalian orders or families, offer the most practical advantages for testing spill-over potential and, in this 
study, were a panel that demonstrated discriminatory power for the infection potential of the novel viruses tested.
The continued search for novel viruses in wildlife species, particularly in regions of the world where encroach-
ment of humans and livestock into wildlife habitats is increasing, such as sub-Saharan Africa, is imperative if we 
are going to be able to identify disease in these regions caused by novel pathogens. New discoveries of wildlife 
viruses alone, however, will not inform risks to livestock or public health. Viral phylogeny and other signals of 
spill-over potential, such as the serosurveillance results that guided this study, are required to identify potential 
new health threats22. The Achimota viruses described in this paper demonstrate ability to cross the species barrier 
and may be causing undiagnosed disease in domesticated animals and humans within the wide geographical 
range of the bat reservoir species, Eidolon helvum.
Materials and Methods
Animals, accommodation, handling and biosafety. Ferrets were acquired from a colony free of infec-
tion by influenza H1 and H3 subtypes. Two male ferrets aged 11–13 months, four female guinea pigs, five female 
BALB/c mice aged 12 wks, and five female BALB/c mice aged over 12 months were used in each of the AchPV1 and 
AchPV2 observational studies. Eight female ferrets and eight female guinea pigs were used for the AchPV2 time 
course study. The animal husbandry methods and experimental design were approved by the CSIRO Australian 
Animal Health Laboratory’s Animal Ethics Committee (approvals AEC 1608 and AEC 1621) and were carried out 
in accordance with the relevant guidelines and regulations. Animals were housed at Biosafety Level 3 (BSL-3) in 
conventional caging systems to facilitate the expression and monitoring of natural behaviours, given complete pre-
mium dry food appropriate to the species, dietary treats, and provided with water ad libitum. Room temperature 
was maintained at 22 °C with 15 air changes per hour and humidity varied between 40 and 60%. Before any manip-
ulation occurred, such as exposure to virus, collection of clinical samples or euthanasia, animals were immobilised 
with a mixture of ketamine HCl (Ketamil®: 5 mg/kg in ferrets, 16 mg/kg in guinea pigs, 75 mg/kg in mice) and 
medetomidine (Domitor®: 50 µg/kg in ferrets, 20 µg/kg in guinea pigs, 1 mg/kg in mice) by intramuscular or intra-
peritoneal (mice) injection. Where indicated, reversal was achieved with atipamazole (Antisedan®) administered 
by intramuscular (ferrets) or intraperitoneal (guinea pigs and mice) injection at 50% of the medetomidine volume. 
All animals were implanted subcutaneously with temperature-sensing microchips (Lifechip®). Staff wore powered 
air purifying respirators, coveralls, impervious gloves and boots while in animal rooms.
Animal infections and sampling. For the observational studies, animals were exposed to either AchPV1 
or AchPV2, previously isolated, grown and titrated in vero cells. Animal inoculation stocks were prepared as 
follows: after initial virus isolation, a parent stock of each virus was grown in vero cells. These parent stocks were 
then purified by three rounds of limiting dilution in vero cells. Finally, an animal inoculation stock was prepared 
from the third limiting dilution, resulting in a passage number of 6 times in vero cells from original isolation. The 
sequence of the animal inoculation stock was not compared to the original sequence of the isolated virus. Ferrets 
and guinea pigs were given 105 TCID50 oronasally in 1 ml of inoculum (500 µl oral and 500 µl nasal), and mice 
were given 103 TCID50 intranasally in 50 µl of inoculum. General clinical observations were documented daily 
prior to as well as post challenge (pc). Animals were weighed and their temperatures recorded daily. Animals were 
euthanased at either a predetermined humane endpoint or 21 days pc. Blood was collected for serology prior to 
virus exposure and at euthanasia. Tissues were not collected for the observational studies.
For the subsequent time course studies, ferrets and guinea pigs were exposed oronasally to 105 TCID50 
AchPV2, prepared as described above, in 1 ml of inoculum (500 µl oral and 500 µl nasal). Two animals were 
pre-allocated for euthanasia on each of days 6, 8, 10 and 21 pc in order to obtain preliminary data on pathogenesis 
and tissue tropism at likely key time-points for such an acute infection study. Nasal washes (ferrets only), oral 
and rectal swabs and blood samples, both in EDTA and for serum preparation, were collected from all avail-
able animals at days 2, 4, 6, 8, 10 and 21 pc. Clinical samples were collected into tubes containing PBS with 
antibiotic-antimycotic (Invitrogen) for virus isolation and into tubes containing MagMAX viral lysis buffer 
(Ambion) for RNA extraction. While under anaesthesia, rectal temperatures of ferrets were recorded by digital 
thermometer.
At post mortem examination of animals used for the AchPV2 time course study, the following tissues were 
collected for histology, immunohistochemistry, viral genome detection and virus isolation: nasal turbinates, 
tonsil, retropharyngeal lymph node, trachea, lung, hilar lymph node, bronchial lymph node, spleen, heart, kid-
ney, liver, bladder and brain. Stomach, small and large intestine, pancreas, adrenal gland, ovary and uterus were 
also collected for histology and immunohistochemistry. Tissues were collected into tubes containing either 
neutral buffered 10% formalin (for histology and immunohistochemistry) or PBS plus antibiotic-antimycotic 
(Invitrogen) and homogenisation beads, homogenised using a bead beater, and clarified by centrifugation (for 
virus isolation or viral RNA detection).
RNA extraction and Reverse Transcriptase-quantitative Polymerase Chain Reaction. For viral 
genome detection, RNA was extracted from tissue, blood and swab samples using the MagMAX viral RNA isolation 
kit (Ambion) following the manufacturers guidelines. A novel Reverse Transcriptase-quantitative Polymerase Chain 
Reaction (RT-qPCR), was designed that specifically targets the nucleoprotein gene (N-gene) of AchPV2. For the 
design process, the N-gene sequence of AchPV2 (JX051320), as well as other closely related paramyxoviruses including 
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SosPV, MenPV and TioPV, was retrieved from GenBank. Subsequently, sequence alignments were performed using 
Geneious software (Version 8.1, Biomatters). Potential primer and probe regions distinctive of AchPV2 were iden-
tified from these alignments and candidate primers and probes assessed using the Primer Express 3.0.1 program 
(Thermofisher-Applied Biosystems). An assay spanning the 625–700 nucleotide region (75 nucleotides in length) of 
the N-gene of AchPV2 (JX051320), consists of forward primer: D-715 (5′-GCAGGTCTGGATCACAGTATGC-3′), 
reverse primer D-716 (5′-TGCCAGTCGCCTCTCATCT-3′), and probe
D-717 (5′[FAM]-TGCATGACAGCATATGATCAGCCCACT-[BHQ-1]-3′. The optimized primer and 
probe concentrations and assay conditions were as follows: forward primer (D-715) and reverse primer 
(D-716): 300 nM, probe (D-716): 200 nM. Reactions were performed using AgPath-ID One-Step RT-PCR Kit 
(Thermofisher-Ambion) on an AB7500 Fast instrument using the thermal cycle: 1 cycle of 45 °C 10 min, 95 °C 
10 min followed by 45 cycles of 95 °C 15 sec, 60 °C 45 sec. To determine the assay efficiency, a standard curve was 
generated using ten-fold serial dilutions of AchPV2 RNA and was found to be 95%. The analytical specificity was 
investigated using a range of available paramyxoviruses, namely Newcastle disease virus, J virus, HeV, NiV and 
closely related rubulaviruses (MenPV and TioPV) and only the reference AchPV2 was detected by the RT-qPCR. 
For interpretation of results duplicate samples producing an average cycle threshold (Ct) less than 38 were con-
sidered positive.
Virus isolation. Vero cell monolayers were grown in 96 well tissue culture plates to 80% confluency in 
cell media (Minimal Essential Medium containing Earle’s salts and supplemented with 2 mM glutamine, 
antibiotic-antimycotic and 10% fetal calf serum).
Swab media and blood were serially diluted 10 fold and 50 µl added to each well. Supernatant from centrifuged 
tissue homogenate was serially diluted 10 fold and 50 µl added to each well. Vero cell monolayers were observed 
for viral CPE seven days post infection.
Serology. Serum was collected prior to viral challenge and again at euthanasia, and tested using a standard 
virus neutralisation test. Serial two-fold dilutions of test sera were prepared in duplicate in a 96-well tissue culture 
plate in 50 µL cell media (Minimal Essential Medium containing Earle’s salts and supplemented with 2 mM glu-
tamine, antibiotic-antimycotic and 10% fetal calf serum). An equal volume of either AchPV1 or AchPV2 working 
stock containing 200 TCID50 was added and the virus-sera mix incubated for 30 min at 37 °C in a humidified 
5% CO2 incubator. 100 µL of Vero cell suspension containing 2 × 105 cells/mL was added and the plate incu-
bated at 37 °C in a humidified 5% CO2 incubator. The plate was observed for viral CPE after seven days and the 
serum neutralisation titre determined as being the dilution where 100% neutralisation was observed in duplicate 
wells. Serum samples that showed no neutralisation of virus in duplicate wells at the starting dilution (1:10) were 
described as negative.
Histology and immunohistochemistry. Formalin-fixed tissues were processed into paraffin wax and pre-
pared into 4 µm thick sections using routine histological methods. For immunohistochemistry, antigen retrieval 
was performed using the DAKO PT LINK machine (Dako, Glostrup, Denmark) by heating the tissue sections 
to 97 °C for 30 minutes and then cooling to 70 °C in the Envision Flex Target high pH retrieval solution (DAKO) 
and washing for 5 minutes in Tris Buffer. After this, endogenous peroxidases were quenched by the addition of 
3% H2O2 solution. Tissue sections were then incubated with the primary antibody, polyclonal rabbit antisera 
raised against AchPV2, at a dilution of 1:2000. The visualization system used was Envision FLEX/horseradish 
peroxidase (HRP) conjugated with 3-Amino-9-Ethylcarbazole (AEC) chromogen (DAKO AEC + substrate chro-
magen K3469). Slides were then counterstained with Lillie-Mayer haematoxylin (Australian Biostain, Traralgon, 
Australia) and Scotts tap water before mounting. A duplicate set of tissue sections were stained with hematoxylin 
and eosin stain for histological examination using routine methods.
Statistical analysis. In the time-course study, bodyweights and rectal temperatures of ferrets, and body-
weights and microchip temperatures of guinea pigs, up to and including day 6 pc were compared using a repeated 
measures ANOVA followed by Dunnett’s multiple comparisons test (GraphPad Prism 7.02).
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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